Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
about
Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal CancerPredictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of OptionsFOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapyERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.Colorectal cancer in Chinese patients: current and emerging treatment options.ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting.Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy.Nucleotide Excision Repair Gene ERCC2 and ERCC5 Variants Increase Risk of Uterine Cervical Cancer.Role of solute carrier transporters in pancreatic cancer: a review.Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers.Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis.A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy.DNA base excision repair proteins APE-1 and XRCC-1 are overexpressed in oral tongue squamous cell carcinoma.The Differential Expression of Core Genes in Nucleotide Excision Repair Pathway Indicates Colorectal Carcinogenesis and Prognosis.Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer
P2860
Q26738587-A01C89AA-3AA1-4F28-9E29-97AAA7B88269Q26738655-1EA5418C-4E17-4261-8E0F-34A2B0B3F252Q26851060-4C903507-A9AB-44E7-ADF9-9C19A82C34D1Q33722508-A50E915A-8267-45DD-9BF5-F40143D9DFD6Q34352595-72B12941-200C-4329-9A9F-BA99075218B6Q35833376-5DC6348B-62E0-4C0D-8904-A3E273F11C5AQ35932040-7C4E30D0-3949-44E5-B1F1-831AF7CE275EQ36832230-E24C52E3-47D5-4C46-AFCD-50E2F60E2A83Q38236028-FA5FB9F8-5102-49A6-9DC1-BF9FC70127F7Q38835268-532ED32A-BA70-4213-A57B-751851B0FC97Q40979612-7BAC2FF8-1107-4BEB-8D42-F6DD2F4E528AQ41205616-CCB67555-67B1-4723-A552-6F854AD944BDQ41686298-93E8C506-01DA-439C-AC35-6AFA64347B29Q49898050-57F84923-1F4A-432B-BE18-F36F8C73A379Q50947717-27E26032-45C8-40C8-BC99-9EACDCB6CCB5Q51281400-A10CE873-403B-4AC5-AD6E-1506424B153FQ52641380-8B71FC2F-46D6-4B91-ADEC-75B41245C1F8Q58695421-33DF478B-13C2-482E-9C71-26757B15BA4C
P2860
Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Predictive value of ERCC1, ERC ...... OLFOX-4 adjuvant chemotherapy.
@en
Predictive value of ERCC1, ERC ...... OLFOX-4 adjuvant chemotherapy.
@nl
type
label
Predictive value of ERCC1, ERC ...... OLFOX-4 adjuvant chemotherapy.
@en
Predictive value of ERCC1, ERC ...... OLFOX-4 adjuvant chemotherapy.
@nl
prefLabel
Predictive value of ERCC1, ERC ...... OLFOX-4 adjuvant chemotherapy.
@en
Predictive value of ERCC1, ERC ...... OLFOX-4 adjuvant chemotherapy.
@nl
P2093
P2860
P921
P356
P1476
Predictive value of ERCC1, ERC ...... OLFOX-4 adjuvant chemotherapy.
@en
P2093
Chee-Yin Chai
Cheng-Jen Ma
Chih-Hung Lin
Ching-Wen Huang
Chun-Ming Huang
Hsiang-Lin Tsai
Jaw-Yuan Wang
Ming-Yii Huang
P2860
P304
P356
10.1002/JSO.23422
P577
2013-08-31T00:00:00Z